Research programme: targeted mutant RAS inhibitors - REVOLUTION Medicines
Alternative Names: RAS targeting inhibitors - REVOLUTION Medicines; RAS(ON) inhibitors - REVOLUTION MedicinesLatest Information Update: 28 Aug 2023
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 09 May 2022 REVOLUTION Medicines announces intention to nominate a fifth RAS (ON) inhibitor development candidate in the second half of 2022
- 22 Nov 2021 Preclinical pharmacodynamics data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2021)